S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A

• Florian Perner,
• Homa Rahnamoun,
• Daniela V. Wenge,
• Yijun Xiong,
• Athina Apazidis,
• Disha Anand,
• Charlie Hatton,
• Yanhe Wen,
• Shengqing Gu,
• X Shirley Liu,
• Wenbin Xiao,
• Sheng F. Cai,
• Ross L. Levine,
• Gerard M. Mcgeehan,
• Scott A. Armstrong

Affiliations

Florian Perner

1 University Medicine Greifswald, Internal Medicine C, Greifswald, Germany

Homa Rahnamoun

2 Dana-Farber Cancer Institute, Boston, United States

Daniela V. Wenge

2 Dana-Farber Cancer Institute, Boston, United States

Yijun Xiong

2 Dana-Farber Cancer Institute, Boston, United States

Athina Apazidis

2 Dana-Farber Cancer Institute, Boston, United States

Disha Anand

1 University Medicine Greifswald, Internal Medicine C, Greifswald, Germany

Charlie Hatton

2 Dana-Farber Cancer Institute, Boston, United States

Yanhe Wen

2 Dana-Farber Cancer Institute, Boston, United States

Shengqing Gu

2 Dana-Farber Cancer Institute, Boston, United States

X Shirley Liu

2 Dana-Farber Cancer Institute, Boston, United States

Wenbin Xiao

4 Memorial Sloan Kettering Cancer Center New York, New York, United States

Sheng F. Cai

4 Memorial Sloan Kettering Cancer Center New York, New York, United States

Ross L. Levine

4 Memorial Sloan Kettering Cancer Center New York, New York, United States

Gerard M. Mcgeehan

5 Syndax Pharmaceuticals Inc, Waltham, United States

Scott A. Armstrong

2 Dana-Farber Cancer Institute, Boston, United States